Latest OSI Pharmaceuticals Stories
TOKYO, Jan. 10, 2011 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that it has engaged Citigroup Global Markets Inc. to conduct, in conjunction with executive management, a review of the Company's strategic alternatives with regard to its Prosidion subsidiary.
BURLINGTON, Mass., Oct.
TOKYO, June 9 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc.
TOKYO, March 31 /PRNewswire/ -- Astellas Pharma Inc.
TOKYO, March 15 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today released the following statement in response to OSI Pharmaceuticals' (Nasdaq: OSIP) rejection of Astellas' tender offer for $52.00 per share.
TOKYO, March 2 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.
TOKYO, March 1 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.
CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(Â®) (erlotinib) in patients with non-small cell lung cancer (NSCLC).